Msi1 Promotes Tumor Progression by Epithelial-to-mesenchymal Transition in Cervical Cancer
Overview
Affiliations
Musashi1 (Msi1) is an RNA-binding protein that has been reported to be a pivotal regulator in tumorigenesis and progression in several cancers. However, its function and mechanism in cervical cancer is still unknown. In this study, Msi1 expression was found elevated in cervical cancers by immunohistochemistry and correlated with poor outcomes. Then, endogenous Msi1 was silenced in cervical cancer cell lines by short hairpin RNA, and its function and mechanism were determined. The results showed that the silencing of Msi1 in SiHa and HeLa cells inhibited the cells' migratory and invasive abilities in vitro and tumor progression in vivo. Epithelial-to-mesenchymal transition (EMT) markers were down-regulated, and Wnt activity was inhibited by the silencing of Msi1. In clinical tissues, positive correlations between Msi1 and EMT markers were found. In conclusion, Msi1, a diagnostic marker and potential therapeutic target, promoted the EMT progression through activation of the Wnt signaling pathway in cervical cancers, thereby contributing to poor prognosis.
The Musashi-1-type 2 deiodinase pathway regulates astrocyte proliferation.
Mohacsik P, Halmos E, Doroghazi B, Ruska Y, Wittmann G, Bianco A J Biol Chem. 2024; 300(7):107477.
PMID: 38879014 PMC: 11301063. DOI: 10.1016/j.jbc.2024.107477.
Targeting Cervical Cancer Stem Cells by Phytochemicals.
Tripathi T, Yadav J, Janjua D, Chaudhary A, Joshi U, Senrung A Curr Med Chem. 2024; 31(32):5222-5254.
PMID: 38288813 DOI: 10.2174/0109298673281823231222065616.
Bi X, Lou P, Song Y, Sheng X, Liu R, Deng M Oncogene. 2021; 40(29):4832-4845.
PMID: 34155343 DOI: 10.1038/s41388-021-01873-8.
Musashi-1-A Stemness RBP for Cancer Therapy?.
Bley N, Hmedat A, Muller S, Rolnik R, Rausch A, Lederer M Biology (Basel). 2021; 10(5).
PMID: 34062997 PMC: 8148009. DOI: 10.3390/biology10050407.
Msi1 inhibits cervical cancer cell apoptosis by downregulating BAK through AKT signaling.
Liu X, Zhang Y, Zheng P, Cui N J Cancer. 2021; 12(8):2422-2429.
PMID: 33758618 PMC: 7974892. DOI: 10.7150/jca.52950.